PTC Therapeutics to Participate at Upcoming Investor Conferences

WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conference 2026 Monday, March 2 at 9:50 a.m.

PRNewsWire • Feb 23, 2026

PTC Therapeutics: Sephience As A Major Growth Driver

PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Huntington's disease and Vatiquinone for Friedreich's ataxia, offer significant upside but carry clinical trial risks. PTCT's competitive edge lies in its oral small molecule platform, collaborative development model, and strong pricing power in ultra-rare disease markets.

Seeking Alpha • Feb 23, 2026

PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 20, 2026

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.

PRNewsWire • Feb 19, 2026

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago.

Zacks Investment Research • Feb 20, 2026

PTC Therapeutics (PTCT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Feb 20, 2026

Ahead of PTC Therapeutics (PTCT) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

Zacks Investment Research • Feb 16, 2026

PTC Therapeutics Provides Regulatory Update on Translarna™

WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following U.S. Food and Drug Administration (FDA) feedback on the application review.

PRNewsWire • Feb 12, 2026

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 12, 2026

PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m.

PRNewsWire • Feb 5, 2026